Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price

Immuno-Oncology Drugs Market 2022 – By Type (Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others), By Therapeutic Application (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application), By End-Users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), And By Region, Opportunities And Strategies – Global Forecast To 2031 

Immuno-Oncology Drugs Global Market Opportunities And Strategies To 2031

Starting Price : $5000.00 $3500.00 | Pages : 303 | Published : June 2022 | | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Immuno-Oncology Drugs Market Definition

The immuno-oncology drugs market consists of sales of immuno-oncology drugs by entities (organizations, sole traders and partnerships) that are used for the treatment of cancer. Immuno-oncology is the artificial stimulation of the immune system to treat cancer, improving the immune system's ability to fight the disease. The market consists of revenue generated by the companies’ manufacturing immuno-oncology drugs by the sales of these products.

Book your 30 minutes free consultation with our research experts

Contact Us

Immuno-Oncology Drugs Market Size

The global immuno-oncology drugs market reached a value of nearly $67,882.2 million in 2021, having increased at a compound annual growth rate (CAGR) of 19.5% since 2016. The global immuno-oncology drugs market size is expected to grow from $67,882.2 million in 2021 to $116,237.0 million in 2026 at a rate of 11.4%. The global immuno-oncology drugs market size is then expected to grow at a CAGR of 10.0% from 2026 and reach $186,918.8 million in 2031.  

Growth in the historic period in the immuno-oncology drugs market resulted from the rise in the number of cancer cases, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical R&D expenditure. The market was restrained by high cost of immuno-oncology therapies, low healthcare access, pricing pressures from regulators, high R&D costs, and patent expiration of drugs.  

Going forward, increasing investment in immuno-oncology, rising focus on immunotherapy drugs for cancer treatment, product innovations through strategic collaborations and increasing older population are expected to drive the market. Factors that could hinder the growth of the market in the future include side effects associated with immunotherapies and rising popularity of alternative therapies and natural remedies.

Immuno-Oncology Drugs Market Drivers

The key drivers of the immuno-oncology drugs market include:

Product Innovations Through Strategic Collaborations

Product innovations through strategic collaborations are contributing to the growth of the immun0-oncology drugs market. In January 2021, Boehringer Ingelheim, a Germany based pharmaceutical company collaborated with Enara Bio for an undisclosed amount. This collaboration combines Boehringer Ingelheim’s approach to tackling cancer through pairing leading science with innovative immune-oncology platforms, like oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification. Enara Bio is a UK based science-led company targeting the T-cell/cancer-cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population.  In September 2020, AbbVie, a US-based biopharmaceutical company collaborated with I-Mab for an undisclosed amount. This collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. I-Mab is a Shanghai-based biotech company.  Therefore, strategic collaborations are expected to drive the growth of the immuno-oncology market.

Immuno-Oncology Drugs Market Restraints

The key restraints on the immuno-oncology drugs market include:

Rising Popularity Of Alternative Therapies And Natural Remedies

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of immun0-oncology drug companies. Treatments in the fields of homoeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anti-cancer properties, for example, Andrographis paniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, the above reasons are affecting the immun0-oncology drug’s sales. Also, the global homoeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. This trend is expected to continue during the forecast period and limit the demand for immun0- oncology drugs.

Immuno-Oncology Drugs Market Trends

Major trends shaping the immuno-oncology drugs market include:

Development Of Personalized Cancer Vaccines

Drug manufacturers are investing in developing personalized cancer vaccines, and few have reached clinical trial phases. Pharmaceutical companies are combining genetic sequencing and precision medicine to create new drug therapies and cancer treatments that are designed to treat specific patients. DNA vaccines are easy and cost effective to manufacture as compared with other neoantigen vaccine. For instance, in April 2021, Washington University School of Medicine researcher’s in shown that personalized cancer vaccines made using DNA can program the immune system to attack malignant tumors, including breast and pancreatic cancers. The findings also shown that a personalized DNA vaccine coupled with other immunotherapies can generate a robust immune response capable of shrinking breast cancers in mice.

Development And Increasing Demand For Next-Generation Biologics

Antibody-drug conjugates (ADCs) are being used to treat several chronic diseases including cancer. ADCs are monoclonal antibodies that have the ability to discriminate between healthy and diseased tissues and kill the diseased tissues when detected. ADCs are being used in cancer treatment by attaching them to cancer-killing drugs that kill cancerous cells, leaving healthy tissues unaffected.  

Companies in the immune-oncology drugs market are investing in technologies to develop next-generation biologics such as ADCs, bispecifics, fusion proteins, cell and gene therapy that will be more effective. These next-generation biologics are expected to have better potency against the target disease as well as have the ability to treat more than one aspect of the disease.   They are being manufactured with the help of technology, along with drug delivery systems. Some of the next-generation biologics brands include Kadcyla and Adcetris. Companies such as Roche, Bristol-Myers Squibb, and Novartis are investing heavily in the development of next-generation biologics.  The scope of market growth seems to be very high as the technology giant Samsung, through its subsidiary Samsung BioLogics Co., is investing around $740 million for the production of next-gen biologics.

Opportunities And Recommendations In The Immuno-Oncology Drugs Market

Opportunities –The top opportunities in the immuno-oncology drugs market segmented by type will arise in other monoclonal antibodies segment, which will gain $17,982.0 of global annual sales by 2026. The top opportunities in the immuno-oncology drugs market segmented by therapeutic application will arise in other therapeutic application segment, which will gain $15,867.8 million of global annual sales by 2026. The top opportunities in the immuno-oncology drugs market segmented by end-users will arise in hospitals segment, which will gain $23,174.2 million of global annual sales by 2026. The immuno-oncology drugs market size will gain the most in the USA at $22,184.1 million.

Recommendations –To take advantage of the opportunities, The Business Research Company recommends the immuno-oncology drugs companies to focus on new product launches, focus on immuno-oncology combination therapies, expand in emerging markets, increase merger and acquisition activity, provide competitively priced offerings, focus on securing long-term supply contracts with healthcare institutions, offer value-based pricing, focus on educating consumers about immuno-oncology drugs and focus on the elderly population.

Immuno-Oncology Drugs Market Segmentation

The immuno-oncology drugs market is segmented by type, by therapeutic application, and by end-users.
By Type –
The immuno-oncology drugs market is segmented by type into
    • a) Immune Checkpoint Inhibitors
    • b) Immune System Modulators
    • c) Other Monoclonal Antibodies
    • d) Cancer Vaccines
    • e) Others
The other monoclonal antibodies segment was the largest segment of the immuno-oncology drugs market segmented by type, accounting for 40.3% of the total in 2021. Going forward, the others segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by type, at a CAGR of 26.8% during 2021-2026.
By Therapeutic Application –
The immuno-oncology drugs market is segmented by therapeutic application into
    • a) Melanoma
    • b) Lung Cancer
    • c) Blood Cancer
    • d) Renal Cell Carcinoma
    • e) Bladder Cancer
    • f) Other Therapeutic Application
The other therapeutic application was the largest segment of the immuno-oncology drugs market segmented by therapeutic application, accounting for 37.9% of the total in 2021. Going forward, the bladder cancer segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by therapeutic application, at a CAGR of 20.7% during 2021-2026.
By End-Users –
The immuno-oncology drugs market is segmented by end-users into
    • a) Hospitals
    • b) Clinics
    • c) Ambulatory Surgical Centers
    • d) Others
The hospitals segment was the largest segment of the immuno-oncology drugs market segmented by end-users, accounting for 45.7% of the total in 2021. Going forward, hospitals segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by end-users, at a CAGR of 11.8% during 2021-2026.
By Geography- The immuno-oncology drugs market is segment by geography into
    • o Asia Pacific
      • •  China
      • •  Japan
      • •  India
      • •  Australia
      • •  Indonesia
      • •  South Korea
      • o North America
      • • USA
      o South America
      • • Brazil 
      o Western Europe
      • • UK 
      • • Germany 
      • • France 
      o Eastern Europe
      • • Russia 
      o Middle East
      o Africa
North America was the largest region in the immuno-oncology drugs market, accounting for 48.3% of the total in 2021. It was followed by the Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the immuno-oncology drugs market will be Middle East and South America where growth will be at CAGRs of 14.0% and 12.8% respectively during 2021-2026. These will be followed by Africa and Eastern Europe, where the markets are expected to register CAGRs of 12.5% and 12.2% respectively during 2021-2026.

Immuno-Oncology Drugs Market Competitive Landscape

Major Competitors are:

  • F. Hoffmann-La Roche Ltd.
  • Merck & Co.
  • Bristol-Myers Squibb Company
  • Amgen Inc
  • Johnson & Johnson

    • Other Competitors Include:

  • AstraZeneca Plc
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Arlak Biotech
  • Healthkind Labs Pvt. Ltd.
  • SwisscheM Healthcare Pvt.Ltd
  • Apikos Pharma
  • Kolaz biotech
  • CStone Pharma
  • CARsgen Therapeutics
  • JW Therapeutics
  • BeiGene
  • Takeda Pharmaceuticals
  • Astellas Pharma Inc
  • Otsuka Pharmaceutical Co, Ltd
  • Legend Biotech Co
  • Zai Lab
  • Daiichi Pharmaceutical and Sankyo
  • AQVIDA GmbH
  • Baxter International Inc.
  • GlaxoSmithKline plc
  • Affimed Therapeutics
  • Autolus Therapeutics
  • Cellectis
  • Celyad
  • GammaDelta Therapeutics
  • Immunocore
  • European Medical Center (EMC)
  • Yauza Medical Center (Moscow)
  • Celon Pharma
  • Veropharm
  • Biocad
  • Selvita
  • OncoArendi Therapeutics Mabion
  • Fate Therapeutics
  • Forty-Seven
  • Arcus Biosciences
  • Gritstone Oncology
  • Rakuten Medical
  • Rubius Therapeutics
  • Allogene Therapeutics
  • Celgene Corporation
  • Bayer AG
  • Incyte Corporation
  • Recepta Biopharma
  • CSC Pharmaceuticals International
  • Blanver EN
  • Sandoz Brazil
  • Life Pharma
  • Julphar
  • NewBridge Pharmaceuticals
  • Eurolab

      • Table Of Contents

      1. Immuno-Oncology Drugs Market Executive Summary

      2. Table of Contents

      3. List of Figures

      4. List of Tables

      5. Report Structure

      6. Introduction

      6.1. Segmentation By Geography

      6.2. Segmentation By Type

      6.3. Segmentation By Therapeutic Application

      6.4. Segmentation By End Users

      7. Immuno-Oncology Drugs Market Characteristics

      7.1. Market Definition

      7.2. Market Segmentation By Type

      7.2.1. Immune Checkpoint Inhibitors

      7.2.2. Immune System Modulators

      7.2.3. Other Monoclonal Antibodies

      7.2.4. Cancer Vaccines

      7.2.5. Others

      7.3. Market Segmentation By Therapeutic Application

      7.3.1. Melanoma

      7.3.2. Lung Cancer

      7.3.3. Blood Cancer

      7.3.4. Renal Cell Carcinoma

      7.3.5. Prostate Cancer

      7.3.6. Bladder Cancer

      7.3.7. Others

      7.4. Market Segmentation By End User

      7.4.1. Hospitals

      7.4.2. Clinics

      7.4.3. Ambulatory Surgical Centers

      7.4.4. Cancer Research Institutes

      8. Immuno-Oncology Drugs Market Trends and Strategies

      8.1. Increasing Usage of Microneedle Pills

      8.2. Development Of Personalized Cancer Vaccines

      8.3. Increase In Acquisition Activity Among Immuno-Oncology Drug Market Players

      8.4. Development And Increasing Demand For Next-Generation Biologics

      8.5. Investment In Artificial Intelligence For Oncology Drugs

      8.6. Use Of 3D Printing To Test New Oncology Drugs

      8.7. Immuno-Oncology Combination Therapies

      8.8. CAR-T Cell Therapy

      9. COVID Impact On The Immuno-Oncology Drugs Market

      9.1. COVID-19 Pandemic Effects On Cancer Patients and Survivors

      9.2. Clinical Trial Delays

      9.3. Low Usage Of Drugs

      9.4. Supply Chain Issues

      9.5. Future Outlook

      10. Global Immuno-Oncology Drugs Market Size And Growth

      10.1. Market Size

      10.2. Historic Market Growth, 2016 – 2021, Value ($ Million)

      10.2.1. Drivers Of The Market 2016-2021

      10.2.2. Restraints On The Market 2016 – 2021

      10.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      10.3.1. Drivers Of The Market 2021 – 2026

      10.3.2. Restraints On The Market 2021 – 2026

      11. Global Immuno-Oncology Drugs Market Segmentation

      11.1. Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.2. Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.3. Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12. Immuno-Oncology Drugs Market, Regional And Country Analysis

      12.1. Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.2. Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13. Asia-Pacific Immuno-Oncology Drugs Market

      13.1. Asia-Pacific Immuno-Oncology Drugs Market Overview

      13.1.1. Region Information

      13.1.2. Market Information

      13.1.3. Background Information

      13.1.4. Government Initiatives

      13.1.5. Regulations

      13.1.6. Regulatory Bodies

      13.1.7. Major Associations

      13.1.8. Taxes Levied

      13.1.9. Corporate Tax Structure

      13.1.10. Investments

      13.1.11. Major Companies

      13.2. Asia-Pacific Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.3. Asia-Pacific Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.4. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.5. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.6. Asia-Pacific Immuno-Oncology Drugs Market: Country Analysis

      13.7. China Immuno-Oncology Drugs Market

      13.8. China Immuno-Oncology Drugs Market Overview

      13.8.1. Region Information

      13.8.2. Market Information

      13.8.3. Background Information

      13.8.4. Government Initiatives

      13.8.5. Regulations

      13.8.6. Regulatory Bodies

      13.8.7. Major Associations

      13.8.8. Taxes Levied

      13.8.9. Corporate Tax Structure

      13.8.10. Investments

      13.8.11. Major Companies

      13.9. China Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.10. China Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.11. China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.12. China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.13. India Immuno-Oncology Drugs Market

      13.14. India Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.15. India Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.16. India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.17. India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.18. Japan Immuno-Oncology Drugs Market

      13.19. Japan Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.20. Japan Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.21. Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.22. Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.23. Australia Immuno-Oncology Drugs Market

      13.24. Australia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.25. Australia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.26. Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.27. Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.28. Indonesia Immuno-Oncology Drugs Market

      13.29. Indonesia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.30. Indonesia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.31. Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.32. Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.33. South Korea Immuno-Oncology Drugs Market

      13.34. South Korea Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.35. South Korea Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.36. South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.37. South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14. Western Europe Immuno-Oncology Drugs Market

      14.1. Western Europe Immuno-Oncology Drugs Market Overview

      14.1.1. Region Information

      14.1.2. Market Information

      14.1.3. Background Information

      14.1.4. Government Initiatives

      14.1.5. Regulations

      14.1.6. Regulatory Bodies

      14.1.7. Major Associations

      14.1.8. Taxes Levied

      14.1.9. Corporate Tax Structure

      14.1.10. Investments

      14.1.11. Major Companies

      14.2. Western Europe Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      14.3. Western Europe Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      14.4. Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.5. Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.6. Western Europe Immuno-Oncology Drugs Market: Country Analysis

      14.7. UK Immuno-Oncology Drugs Market

      14.8. UK Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      14.9. UK Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      14.10. UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.11. UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.12. Germany Immuno-Oncology Drugs Market

      14.13. Germany Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      14.14. Germany Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      14.15. Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.16. Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.17. France Immuno-Oncology Drugs Market

      14.18. France Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      14.19. France Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      14.20. France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.21. France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15. Eastern Europe Immuno-Oncology Drugs Market

      15.1. Eastern Europe Immuno-Oncology Drugs Market Overview

      15.1.1. Region Information

      15.1.2. Market Information

      15.1.3. Background Information

      15.1.4. Government Initiatives

      15.1.5. Regulations

      15.1.6. Regulatory Bodies

      15.1.7. Major Associations

      15.1.8. Taxes Levied

      15.1.9. Corporate Tax Structure

      15.1.10. Investments

      15.1.11. Major Companies

      15.2. Eastern Europe Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      15.3. Eastern Europe Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      15.4. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15.5. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15.6. Eastern Europe Immuno-Oncology Drugs Market: Country Analysis

      15.7. Russia Immuno-Oncology Drugs Market

      15.8. Russia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      15.9. Russia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      15.10. Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15.11. Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      16. North America Immuno-Oncology Drugs Market

      16.1. North America Immuno-Oncology Drugs Market Overview

      16.1.1. Region Information

      16.1.2. Market Information

      16.1.3. Background Information

      16.1.4. Government Initiatives

      16.1.5. Regulations

      16.1.6. Regulatory Bodies

      16.1.7. Major Associations

      16.1.8. Taxes Levied

      16.1.9. Corporate Tax Structure

      16.1.10. Investments

      16.1.11. Major Companies

      16.2. North America Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      16.3. North America Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      16.4. North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      16.5. North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      16.6. North America Immuno-Oncology Drugs Market: Country Analysis

      16.7. USA Immuno-Oncology Drugs Market

      16.8. USA Immuno-Oncology Drugs Market Overview

      16.8.1. Region Information

      16.8.2. Market Information

      16.8.3. Background Information

      16.8.4. Government Initiatives

      16.8.5. Regulations

      16.8.6. Regulatory Bodies

      16.8.7. Major Associations

      16.8.8. Taxes Levied

      16.8.9. Corporate Tax Structure

      16.8.10. Investments

      16.8.11. Major Companies

      16.9. USA Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      16.10. USA Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      16.11. USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      16.12. USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      17. South America Immuno-Oncology Drugs Market

      17.1. South America Immuno-Oncology Drugs Market Overview

      17.1.1. Region Information

      17.1.2. Market Information

      17.1.3. Background Information

      17.1.4. Government Initiatives

      17.1.5. Regulations

      17.1.6. Regulatory Bodies

      17.1.7. Major Associations

      17.1.8. Taxes Levied

      17.1.9. Corporate Tax Structure

      17.1.10. Investments

      17.1.11. Major Companies

      17.2. South America Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      17.3. South America Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      17.4. South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      17.5. South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      17.6. South America Immuno-Oncology Drugs Market: Country Analysis

      17.7. Brazil Immuno-Oncology Drugs Market

      17.8. Brazil Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      17.9. Brazil Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      17.10. Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      17.11. Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      18. Middle East Immuno-Oncology Drugs Market

      18.1. Middle East Immuno-Oncology Drugs Market Overview

      18.1.1. Region Information

      18.1.2. Market Information

      18.1.3. Background Information

      18.1.4. Government Initiatives

      18.1.5. Regulations

      18.1.6. Regulatory Bodies

      18.1.7. Major Associations

      18.1.8. Taxes Levied

      18.1.9. Corporate Tax Structure

      18.1.10. Investments

      18.1.11. Major Companies

      18.2. Middle East Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      18.3. Middle East Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      18.4. Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      18.5. Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      19. Africa Immuno-Oncology Drugs Market

      19.1. Africa Immuno-Oncology Drugs Market Overview

      19.1.1. Region Information

      19.1.2. Market Information

      19.1.3. Background Information

      19.1.4. Government Initiatives

      19.1.5. Regulations

      19.1.6. Regulatory Bodies

      19.1.7. Major Associations

      19.1.8. Taxes Levied

      19.1.9. Corporate Tax Structure

      19.1.10. Investments

      19.1.11. Major Companies

      19.2. Africa Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      19.3. Africa Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      19.4. Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      19.5. Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      20. Global Immuno-Oncology Drugs Market Competitive Landscape

      20.1. Company Profiles

      20.2. F. Hoffmann-La Roche Ltd. (Roche)

      20.2.1. Company Overview

      20.2.2. Products And Services

      20.2.3. Business Strategy

      20.2.4. Financial Overview

      20.3. Merck & Co.

      20.3.1. Company Overview

      20.3.2. Products And Services

      20.3.3. Business Strategy

      20.3.4. Financial Overview

      20.4. Bristol-Myers Squibb Company

      20.4.1. Company Overview

      20.4.2. Products And Services

      20.4.3. Business Strategy

      20.4.4. Financial Overview

      20.5. Amgen Inc

      20.5.1. Company Overview

      20.5.2. Products And Services

      20.5.3. Business Strategy

      20.5.4. Financial Overview

      20.6. Johnson & Johnson (J&J)

      20.6.1. Company Overview

      20.6.2. Products And Services

      20.6.3. Business Strategy

      20.6.4. Financial Overview

      21. Key Mergers And Acquisitions In The Immuno-Oncology Drugs Market

      21.1. Sanofi Acquired Amunix Pharmaceuticals Inc.

      21.2. Takeda Yet To Acquire Adaptate Biotherapeutics

      21.3. Takeda Acquired GammaDelta Therapeutics

      21.4. Pfizer Acquired Trillium Therapeutics

      21.5. Amgen Acquired Teneobio Inc.

      21.6. True North Acquired Stake In Biocon Biologics Ltd.

      21.7. PAG Acquired Stake In Hisun BioRay

      21.8. Eli Lilly And Company Acquired Loxo Oncology, Inc.

      21.9. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech

      21.10. Bristol-Myers Squibb Acquired Celgene Corporation

      21.11. Kashiv Pharma, LLC Acquired Adello Biologics

      21.12. Takeda Pharmaceutical Company Limited Acquired Shire Plc

      21.13. GlaxoSmithKline Plc Acquired Tesaro Inc.

      22. Immuno-Oncology Drugs Market Opportunities And Strategies

      22.1. Global Immuno-Oncology Drugs Market In 2026 – Countries Offering Most New Opportunities

      22.2. Global Immuno-Oncology Drugs Market In 2026 – Segments Offering Most New Opportunities

      22.3. Global Immuno-Oncology Drugs Market In 2026 – Growth Strategies

      22.3.1. Market Trend Based Strategies

      22.3.2. Competitor Strategies

      23. Immuno-Oncology Drugs Market, Conclusions And Recommendations

      23.1. Conclusions

      23.2. Recommendations

      23.2.1. Product

      23.2.2. Place

      23.2.3. Price

      23.2.4. Promotion

      23.2.5. People

      24. Appendix

      24.1. Market Data Sources

      24.2. Research Methodology

      24.3. Currencies

      24.4. Research Inquiries

      24.5. The Business Research Company

      24.6. Copyright and Disclaimer

      24.7.

    List Of Tables

      Table 1: Global Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 2: Global Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 3: Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 4: Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 5: Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 6: Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 7: Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 8: Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 9: Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 10: Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 11: Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 12: Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 13: Asia Pacific GDP Per Capita, 2015-2020, $
    • Table 14: Asia-Pacific, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 15: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 16:  Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 17: Asia-Pacific Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 18: Asia Pacific Cancer Prevalence, Estimated Average Expenditure, 2019, $
    • Table 19: Asia-Pacific Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 20: Asia-Pacific Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 21: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 22: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 23: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 24: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 25: China GDP Per Capita, 2015-2020, $
    • Table 26: China, Population By Age Group, 2015-2025, Thousands
    • Table 27:  China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 28: China Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 29: China Cancer Prevalence, Estimated Average Expenditure, 2019, $
    • Table 30: China Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 31: China Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 32: China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 33: China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 34: China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 35: China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 36: India Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 37: India Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 38: India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 39: India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 40: India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 41: India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 42: Japan Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 43: Japan Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 44: Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 45: Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 46: Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 47: Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 48: Australia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 49: Australia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 50: Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 51: Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 52: Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 53: Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 54: Indonesia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 55: Indonesia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 56: Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 57: Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 58: Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 59: Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 60: South Korea Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 61: South Korea Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 62: South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 63: South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 64: South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 65: South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 66: Western Europe GDP Per Capita, 2015-2020, $
    • Table 67: Western Europe, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 68:  Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 69:  Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 70: Western Europe Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 71: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 72: Western Europe Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 73: Western Europe Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 74: Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 75: Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 76: Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 77: Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 78: UK Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 79: UK Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 80: UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 81: UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 82: UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 83: UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 84: Germany Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 85: Germany Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 86: Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 87: Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 88: Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 89: Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 90: France Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 91: France Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 92: France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 93: France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 94: France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 95: France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 96: Eastern Europe GDP Per Capita, 2015-2020, $
    • Table 97: Eastern Europe, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 98:  Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 99:  Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 100: Eastern Europe Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 101: Eastern Europe Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 102: Eastern Europe Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 103: Eastern Europe Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 104: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 105: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 106: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 107: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 108: Russia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 109: Russia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 110: Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 111: Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 112: Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 113: Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 114: North America GDP Per Capita, 2015-2020, $
    • Table 115: North America, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 116:  North America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 117:  North America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 118: North America Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 119: North America Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 120: North America Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 121: North America Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 122: North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 123: North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 124: North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 125: North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 126: USA GDP Per Capita, 2015-2020, $
    • Table 127: USA, Population By Age Group, 2015-2025, Thousands
    • Table 128:  USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 129: USA Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 130: North America Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 131: USA Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 132: USA Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 133: USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 134: USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 135: USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 136: USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 137: South America GDP Per Capita, 2015-2020, $
    • Table 138: South America, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 139:  South America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 140:  South America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 141: South America Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 142: South America Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 143: South America Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 144: South America Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 145: South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 146: South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 147: South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 148: South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 149: Brazil Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 150: Brazil Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 151: Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 152: Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 153: Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 154: Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 155: Middle East GDP Per Capita, 2015-2020, $
    • Table 156: Middle East, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 157:  Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 158:  Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 159: Middle East Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 160: Middle East Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 161: Middle East Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 162: Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 163: Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 164: Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 165: Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 166: Africa GDP Per Capita, 2015-2020, $
    • Table 167: Africa, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 168:  Africa Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 169:  Africa Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 170: Africa Healthcare Services Market Size, 2016-2026, $ Billion
    • Table 171: Africa Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Table 172: Africa Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 173: Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 174: Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 175: Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 176: Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 177: Global Immuno-Oncology Drugs Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Table 178: F. Hoffmann-La Roche Ltd – Financial Performance, $ Billion
    • Table 179: Merck & Co – Financial Performance, $ Billion
    • Table 180: Bristol-Myers Squibb – Financial Performance, $ Billion
    • Table 181: Amgen – Financial Performance, $ Billion
    • Table 182: J&J – Financial Performance, $ Billion
    • Table 183: Global Immuno-Oncology Drugs Market Size Gain ($ Million), 2021 – 2026, By Country
    • Table 184: Global Immuno-Oncology Drugs Market Size Gain ($ Million), Segmentation By Type, 2021 – 2026
    • Table 185: Global Immuno-Oncology Drugs Market Size Gain ($ Million), Segmentation By Therapeutic Application, 2021 – 2026
    • Table 186: Global Immuno-Oncology Drugs Market Size Gain ($ Million), Segmentation By End User, 2021 – 2026
    • Table 187: Immuno-Oncology Drugs - Market Data Sources

    List Of Figures

      Figure 1: Global Immuno-Oncology Drugs Market Segmentation By Type
    • Figure 2: Global Immuno-Oncology Drugs Market Segmentation By Therapeutic Application
    • Figure 3: Global Immuno-Oncology Drugs Market Segmentation By End Users
    • Figure 4: Global Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 5: Global Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 6: Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 7: Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 8: Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 9: Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 10: Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 11: Asia-Pacific Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 12: Asia-Pacific Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 13: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 14: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 15: China Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 16: China Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 17: China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 18: China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 19: India Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 20: India Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 21: India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 22: India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 23: Japan Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 24: Japan Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 25: Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 26: Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 27: Australia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 28: Australia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 29: Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 30: Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 31: Indonesia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 32: Indonesia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 33: Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 34: Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 35: South Korea Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 36: South Korea Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 37: South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 38: South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 39: Western Europe Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 40: Western Europe Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 41: Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 42: Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 43: UK Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 44: UK Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 45: UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 46: UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 47: Germany Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 48: Germany Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 49: Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 50: Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 51: France Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 52: France Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 53: France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 54: France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 55: Eastern Europe Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 56: Eastern Europe Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 57: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 58: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 59: Russia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 60: Russia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 61: Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 62: Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 63: North America Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 64: North America Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 65: North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 66: North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 67: USA Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 68: USA Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 69: USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 70: USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 71: South America Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 72: South America Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 73: South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 74: South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 75: Brazil Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 76: Brazil Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 77: Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 78: Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 79: Middle East Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 80: Middle East Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 81: Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 82: Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 83: Africa Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
    • Figure 84: Africa Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 85: Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 86: Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 87: Global Immuno-Oncology Drugs Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Figure 88: F. Hoffmann-La Roche Ltd.– Financial Performance, $ Billion
    • Figure 89: Merck & Co – Financial Performance, $ Billion
    • Figure 90: Bristol-Myers Squibb – Financial Performance, $ Billion
    • Figure 91: Amgen – Financial Performance, $ Billion
    • Figure 92: J&J – Financial Performance, $ Billion

    The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

    Read More

    The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

    Read More

    Global Anticoagulants Market 2022 – Market Opportunities And Strategies

    Read More

    Latest Digestive Health Supplements Market Growth Study 2022-2026 By The Business Research Company

    Read More

    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

    Read More

    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

    View Report

    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

    View Report

    Enzymes Global Market Report 2024 – By Product Type (Asparaginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products), By Application (Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications), By End User (Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Protein Inhibitors Global Market Report 2024 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies ) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Monoclonal Antibodies (MAs) Global Market Report 2024 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications), By End Users (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Therapeutic Proteins Global Market Report 2024 – By Product Type (Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), By Function (Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics), By Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Oral Biologics & Biosimilar Drugs Global Market Report 2024 – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

    View Report